




RealRate

PHARMACEUTICAL 2015

Theravance Biopharma Inc
Rank 109 of 274

Theravance
Biopharma
Medicines That Make a Difference



The relative strengths and weaknesses of Theravance Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Theravance Biopharma Inc is the variable Net Income, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 313%, being 59% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	275,370
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	41,256
Liabilities, Non-Current	0
Other Assets	52,738
Other Compr. Net Income	-173
Other Expenses	10,422
Other Liabilities	0
Other Net Income	1,865
Other Revenues	11,688
Property and Equipment	9,663
Research and Development	168,522
Selling, General and Administrative Expense	71,647

Output Variable	Value in 1000 USD
Assets	337,771
Liabilities	41,256
Expenses	250,591
Revenues	11,688
Stockholders Equity	296,515
Net Income	-237,038
Comprehensive Net Income	-237,124
BaseVar	321,672
ECR before Limited Liability	216%
Economic Capital Ratio	313%